drugset / Trial / NCT02860780
A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.
Timeline
- Start
- 2016-08-10
- Primary completion
- 2017-05-15
- Completion
- 2017-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Prexasertib | Small molecule | 60 mg | Intravenous |
| Subject | Ralimetinib | Small molecule | 100 mg | Oral |
| Subject | Ralimetinib | Small molecule | 200 mg | Oral |